错误已被科学证据否定证据确定性: 高初步 C-ODD-06

降糖药总体有害，应归入“禁止”之列；达格列净（Forxiga）是“最脏”的药物之一，会杀死大脑；只有服用糖尿病药物和胰岛素的人才会截肢。

安全提示: 请不要因为这一说法而停用医生开具的糖尿病、心脏或肾脏药物；对心力衰竭、肾脏病或心血管疾病患者停用SGLT2抑制剂或GLP-1受体激动剂，会使他们失去一种已被证实的保护作用。如有顾虑，请与主治医生讨论。

简而言之: 该说法错误。大型随机对照试验表明，达格列净和其他几种糖尿病药物能减少死亡、心力衰竭和肾衰竭；没有证据表明达格列净会杀死大脑，而从未服用过糖尿病药物的人也会发生截肢。

结论: 错误：在大型试验中，达格列净和其他几种糖尿病药物能减少死亡、心力衰竭和肾衰竭；没有证据表明达格列净会损害大脑，而从未服用过糖尿病药物的人也会发生截肢。

原始表述
科学评估
科学证据详解
通俗解释
与该说法相关的研究
地区背景
在我的国家适用什么？
参考文献

原始表述

الفورسيجا ده من اقذر من اقذر ما يمكن يعني انا ما شفتش ادويه اخذر منه غير الانسولين

按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。

译文

降糖药总体有害，应归入“禁止”之列；达格列净（Forxiga）是“最脏”的药物之一，会杀死大脑；只有服用糖尿病药物和胰岛素的人才会截肢。

出处

来源状态: 视频转录文本（本人原话）
归属: Elawady (machine transcript)
视频: الغيبوبات السكرية ؟! (打开来源)
发布日期: 2025年4月30日
时间戳: 0:10:28 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
归属的不确定性: Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.

所声称的机制: Drugs block normal metabolism; harm outweighs benefit.
所声称的健康影响: Brain damage, amputation, death
涉及人群: People with diabetes
Elawady 设定的地域限制: none found

来源版本存在差异

来源状态: 视频转录文本（本人原话）
归属: Elawady (machine transcript)
视频: Dr Diaa Al Awady د ضياء العوضي is live! الموت المفاجيء (打开来源)
发布日期: 2025年7月14日
时间戳: 无（转录文本不含时间信息）
归属的不确定性: Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.

来源状态: 档案网站编辑
归属: Archive editors (not Elawady)
出处: https://eltayebat.com/rule/oral-diabetes-drugs/
归属的不确定性: Editorial narrative and study selection written by the archive operators.

يسمع طب ولا غير اللي هيوطي السكر هيتفشخ اللي هياخد انسولين هيتفشخ اللي هياخد دوا جالفس هيتفشخ اللي هياخد فورسيجا هيتفشخ اللي هياخد مونجارو هيتفشخ اللي هياخداني اسمه ايه اللي شبه المونجارو ده اوزمبيك هيتفشخ خلاص اللي [أصوات

Anyone who lowers blood sugar will be harmed: anyone taking insulin, Galvus (vildagliptin), Forxiga (dapagliflozin), Mounjaro (tirzepatide) or Ozempic (semaglutide) will be badly harmed.

来源状态: 视频转录文本（本人原话）
归属: Elawady (machine transcript)
视频: بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًا ذكري يوم ميلادي 😂😂❤️❤️❤️ (打开来源)
发布日期: 2026年3月26日
时间戳: 1:16:53 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
归属的不确定性: Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.

لن أوقف أدويتي الموصوفة بسبب هذا الموقع

altayybat requires users to confirm on entry that they will not stop prescribed medicines because of the site.

来源状态: 第三方网站（非官方）
归属: Third-party site (unofficial; lowest attribution level)
出处: https://altayybat.com/ar/
归属的不确定性: altayybat.com states on its pages that it is educational only and not affiliated with Dr. Diaa Elawady. Lowest attribution level; page fetched 2026-10-25.

المضادات الحيوية وأدوية الضغط والسكري والإنسولين ممنوعة|ويجب استشارة طبيبك الخاص وتحت اشرافه

CONFLICT: mytayibat lists antibiotics, blood-pressure and diabetes drugs and insulin as 'forbidden', adding 'consult your own doctor and under his supervision'.

来源状态: 第三方网站（非官方）
归属: Third-party site (unofficial; lowest attribution level)
出处: https://mytayibat.com/forbidden
归属的不确定性: mytayibat.com is an unofficial third-party site in the sense that it is neither the eltayebat.com archive nor Elawady's own words. Its footer describes it as 'المنصة الرسمية التعليمية لنظام الطيبات' ('the official educational platform of the Tayebat system'), and its pages refer to it as 'the official platform'. This self-description could not be verified: no evidence was found that the site is authorised by Dr. Diaa Elawady's heirs or by the eltayebat.com archive. By contrast, altayybat.com states that it is not affiliated with Dr. Diaa Elawady. Lowest attribution level; page fetched 2026-10-25. original_ar joins two passages of the page with '|'.

科学评估

错误 – 该说法与可靠证据相矛盾。

证据确定性: 高 – 进一步研究极不可能改变该评估。

1. 说法是什么？

Diabetes drugs are net harmful; Forxiga kills the brain; amputations are caused by the drugs.

2. 哪些内容可证实是正确的？

All drugs have side effects (see C-ODD-05); canagliflozin was associated with toe/metatarsal amputations in CANVAS (6.3 vs 3.4 per 1,000 patient-years; HR 1.97) (A-ODD-09).

3. 哪些内容是错误或夸大的？

The same CANVAS trial showed a net cardiovascular benefit (HR 0.86), fewer serious adverse events than placebo (104.3 vs 120.0 per 1,000 patient-years), and amputations also in the placebo group (3.4 per 1,000 patient-years), which contradicts both 'net harmful' and 'amputations happen only to people taking diabetes drugs' (A-ODD-09). Dapagliflozin reduced cardiovascular death or worsening heart failure (HR 0.74) and all-cause death (HR 0.83) in DAPA-HF (I-ODD-04) and reduced death (HR 0.69) and kidney endpoints in DAPA-CKD, which was stopped early for efficacy (I-ODD-03). Empagliflozin reduced all-cause death by 32% (I-ODD-02); canagliflozin reduced kidney failure by 32% (I-ODD-05); liraglutide reduced death (HR 0.85) (I-ODD-06); semaglutide reduced major cardiovascular events (HR 0.74) (I-ODD-07). Higher glucose exposure is associated with more amputations and complications without threshold (I-INS-04). No evidence was found that dapagliflozin damages the brain.

4. 哪些内容仍不明确？

How often the adverse effects of individual drugs occur in Egyptian practice was not reviewed. Whether the amputation signal seen with canagliflozin in CANVAS (A-ODD-09) applies to other drugs of the class was not reviewed here.

5. 哪些研究支持该说法？

None for the claim as stated. A-ODD-09 documents an amputation signal with one drug but also net benefit and amputations on placebo.

6. 哪些研究与该说法相矛盾？

I-ODD-107 (816-trial NMA: all-cause death OR 0.88 for SGLT2i and GLP-1 RA, high certainty), I-ODD-106 (13 blinded SGLT2i trials: kidney progression RR 0.63, CV death RR 0.86; about 26 events avoided vs 2 caused per 1,000 patient-years), I-ODD-105 (DECLARE, dapagliflozin), I-ODD-02, I-ODD-03, I-ODD-04, I-ODD-05, I-ODD-06, I-ODD-07, I-ODD-112, I-ODD-01, I-INS-04, I-ODD-17, I-ODD-126 (NICE 2026), I-ODD-110 (no RCT signal of dementia with SGLT2i), I-ODD-111 (157 of 290 amputees had no diabetes), A-ODD-09.

7. 对德国和欧洲而言情况如何？

European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.

8. 关于埃及的已知情况是什么？

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

9. 合理的实际结论是什么？

在特定患者群体中，有几类糖尿病药物已被证实的获益超过其风险；用药决定应个体化，并与医生共同作出。

评估详情

证据确定性的依据: Multiple large, double-blind RCTs show reductions in death, heart failure and kidney failure (empagliflozin, dapagliflozin, canagliflozin, liraglutide, semaglutide) and metformin reduced mortality in UKPDS 34. Amputations are caused mainly by diabetic neuropathy and vascular disease driven by hyperglycaemia, which predates modern drugs.
来源质量: Own words plus archive placement of drugs in the 'forbidden' section.
地区可推广性: Universal.
个体例外情况: Individual drugs may be unsuitable for individual patients (e.g. SGLT2 in type 1 diabetes or ketosis-prone patients).
说法的地域范围: 普遍性（生物学/医学）
最近审核: 2026年10月26日初步

科学证据详解

已被科学证据否定 – 高质量证据显示情况恰恰相反，或该说法与已确立的生理学知识相矛盾。

研究问题: Are glucose-lowering drugs (in particular dapagliflozin) net harmful, do they damage the brain, and do leg amputations occur only in people taking diabetes drugs or insulin?

研究问题详解 (PICO)

人群

People with type 2 diabetes (and heart failure/CKD)

干预或暴露

Glucose-lowering drugs, especially SGLT2 inhibitors (dapagliflozin) and GLP-1 RAs

对照

Placebo/standard care; people without diabetes treatment

地域范围

universal biology

结局指标

All-cause mortality
Kidney failure, heart failure
Dementia/cognitive outcomes
Lower-limb amputation

研究结果按作者报告呈现。我们的评估见下文。

哪些证据支持该说法？

Canagliflozin heart and kidney trials (CANVAS)

Neal B et al.. N Engl J Med 2017 · PMID 28605608 · DOI 10.1056/NEJMoa1611925 随机对照试验全文，含结构化偏倚风险评估

CANVAS: canagliflozin increased toe/metatarsal amputations.

实际结果
6.3 vs 3.4 per 1,000 patient-years; HR 1.97.
方法学质量
high (RCT) for this outcome, but not replicated in 12 other trials (I-ODD-106)
相关性
indirect - one drug, not 'only' drug users
局限
Signal not replicated; same trial showed net benefit.

原始文献
Very aggressive blood sugar lowering in high-risk type 2 diabetes

Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743 随机对照试验已核查全文

ACCORD: very intensive glucose lowering increased mortality.

实际结果
HR 1.22 (1.01-1.46).
方法学质量
high
相关性
indirect - harm of aggressive targets, not of the drugs as such
局限
Older drug strategies; not applicable to SGLT2i/GLP-1 RA.

原始文献

哪些证据不支持该说法？

816 trials: what each diabetes drug class does and does not do

Shi Q et al.. BMJ 2023 · PMID 37024129 · DOI 10.1136/bmj-2022-074068 Meta分析已核查全文新增

816-trial NMA: SGLT2i and GLP-1 RAs reduce death.

实际结果
All-cause death OR 0.88 (0.83-0.94) and 0.88 (0.82-0.93), high certainty.
方法学质量
high
相关性
direct

原始文献
13 large trials: SGLT2 drugs protect kidneys and heart; ketoacidosis rare

Nuffield Department of Population Health Renal Studies Group; SMART-C Consortium. Lancet 2022 · PMID 36351458 · DOI 10.1016/S0140-6736(22)02074-8 Meta分析已核查全文新增

13 blinded SGLT2i trials: kidney progression -37%, CV death -14%; benefits far exceed DKA/amputation harms.

实际结果
RR 0.63 (0.58-0.69); CV death RR 0.86 (0.81-0.92); about 26 events avoided vs 2 caused per 1,000 patient-years in CKD with diabetes.
方法学质量
high
相关性
direct

原始文献
Dapagliflozin in heart failure

McMurray JJV et al.. N Engl J Med 2019 · PMID 31535829 · DOI 10.1056/NEJMoa1911303 随机对照试验已核查摘要

DAPA-HF: dapagliflozin reduced death in heart failure.

实际结果
All-cause death HR 0.83; CV death/worsening HF HR 0.74.
方法学质量
high (RCT)
相关性
direct for dapagliflozin
局限
Industry-funded.

原始文献

总体证据说明了什么？

基于上述研究的编辑评估——其本身并非研究结果。

哪种观点有更好的证据支持？

Several glucose-lowering drug classes, including dapagliflozin, reduce death, heart failure and kidney failure in large blinded trials. No randomised evidence shows that dapagliflozin damages the brain (dementia OR 1.20, 0.67-2.17, imprecise). More than half of leg amputees in a population registry had no diabetes; in diabetes, amputations are driven by vascular disease and neuropathy linked to high glucose.

为什么有些研究权重更大

Large blinded RCTs and their meta-analyses, plus 2026 guidelines, outweigh the isolated CANVAS amputation signal and ACCORD (which concerned aggressive targets with older drugs).

因果关系是否已确立？ 是，已确立 Benefits are established by RCTs; brain harm and the 'only drug users' amputation statement have no supporting evidence.

仍存在的不确定性

Long-term cognitive effects of SGLT2i (imprecise RCT data).

合理的结论

The claim is false.

为什么研究结果看起来互相矛盾？

ACCORD's excess mortality and the mortality reductions with SGLT2i/GLP-1 RAs concern different interventions (aggressive HbA1c targets with insulin/sulfonylureas vs specific drugs at usual targets). The CANVAS amputation signal differs from 12 other SGLT2i trials (heterogeneity p=0.0007).

这是否取决于国家？

一般生物学效应: Drug pharmacology and physiology are universal.
饮食习惯: Prolonged fasting, Ramadan fasting and very-low-carbohydrate eating change the risk of hypoglycaemia and ketoacidosis with some drugs; relevant in Egypt and among Muslims in Europe.
食品原产地: Not applicable.
污染物: Not applicable.
本国生产条件: Not applicable (same active substances; generics widely used in Egypt).
法律规则: Drug labels and warnings are set by FDA/EMA and national regulators; Egyptian labelling not reviewed.
实际监测数据: No Egypt-specific pharmacovigilance data were found for this outcome.

足以改变结论的地区差异没有可靠数据支持。

统计复核

Benefit-harm balance per 1,000 patient-years – About 26 events avoided vs about 2 caused (CKD with diabetes). 已重新计算
Share of amputees without diabetes – 157 of 290 (54%). 已重新计算
Precision of dementia OR – OR 1.20 (0.67-2.17), SE(log) 0.30: imprecise, no signal. 已重新计算

总体证据的确定性（GRADE，简化版）

主要结局: All-cause mortality with SGLT2i/GLP-1 RA vs placebo
起始等级: 高（随机试验）
结果: 高

由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。

已核查的临床指南和官方声明

ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (Diabetes Care 2026;49 Suppl 1) (2026) · 原始文献
In type 2 diabetes with ASCVD, heart failure or CKD, use SGLT2i and/or GLP-1 RA with proven benefit irrespective of A1C (recs. 9.7, 9.8, 9.10).
NICE: Type 2 diabetes in adults: management (NG28), last updated 18 February 2026 (2026) · 原始文献
Offer modified-release metformin and an SGLT-2 inhibitor to adults with type 2 diabetes without relevant comorbidity (rec. 1.13.1, 2026); benefits outweigh risks for most people.

检索策略

本次审查的文献检索记录（检索式采用原数据库语法）。

数据库	日期	检索式	检索目标	命中数
Europe PMC	2026年10月26日	`(TITLE:"SGLT2" OR TITLE:"sodium-glucose cotransporter 2" OR TITLE:"dapagliflozin" OR TITLE:"SGLT-2") AND (TITLE:dementia OR TITLE:cognitive OR TITLE:stroke OR TITLE:brain) AND (cohort OR "meta-analysis" OR trial)`	双向	122
PubMed	2026年10月26日	`(SGLT2[tiab] OR "sodium-glucose cotransporter-2"[tiab] OR SGLT-2[tiab]) AND dementia[ti] AND (BMJ[ta] OR meta-analysis[pt])`	反对性证据	20
Europe PMC	2026年10月26日	`(TITLE:"amputation") AND (SGLT2 OR canagliflozin OR "glucose-lowering" OR insulin) AND ("meta-analysis" OR cohort)`	支持性证据	228
PubMed	2026年10月26日	`(dapagliflozin[ti] OR "SGLT2 inhibitor*"[ti]) AND (stroke[ti] OR "cerebral"[ti] OR "neurological"[ti] OR "cognitive"[ti]) AND (adverse[tiab] OR harm[tiab] OR risk[tiab])`	支持性证据	30
Europe PMC	2026年10月26日	`(dapagliflozin) AND ("all-cause mortality" OR "death from any cause") AND ("heart failure" OR "chronic kidney disease") AND (randomized OR randomised) AND PUB_TYPE:"Randomized Controlled Trial"`	反对性证据	162
Europe PMC	2026年10月26日	`(Egypt OR Egyptian) AND (SGLT2 OR dapagliflozin OR empagliflozin OR "GLP-1" OR metformin OR insulin) AND ("adverse" OR "outcomes" OR "ketoacidosis" OR amputation)`	双向	14938
NICE NG28 (2026)	2026年10月26日	`Fetched https://www.nice.org.uk/guidance/ng28/chapter/Initial-medicines; chapter Initial medicines`	指南	1
ADA Standards of Care 2026, Section 9 (PubMed Central)	2026年10月26日	`Fetched https://pmc.ncbi.nlm.nih.gov/articles/PMC12690185/; recs. 9.7-9.10. The diabetesjournals.org DOI landing pages returned HTTP 403; the identical article was read in PubMed Central.`	指南	1

待解决的问题

Dedicated long-term cognitive trials of SGLT2 inhibitors.

核查深度如何？

18 项相关研究：7 项核查了全文（其中 4 项进行了结构化偏倚风险评估），11 项基于摘要核查，0 项仅核查了文献信息。尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。

最近一次科学审核: 2026年10月26日

评定结论的变更历史

2026年10月25日 · 第 1 阶段 · 初始评估: 错误 (高)
2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 错误 (高)
New high-quality evidence (I-ODD-106, I-ODD-107, I-ODD-112, NICE 2026) strengthens the existing verdict; amputation and brain components are now addressed with specific evidence (I-ODD-111, I-ODD-110).
新来源: I-ODD-105 I-ODD-106 I-ODD-107 I-ODD-110 I-ODD-111 I-ODD-112 I-ODD-126

通俗解释

这些视频把Forxiga称为最脏的药物之一。然而，纳入数千名患者的大型试验表明，Forxiga和同类药物能减少死亡、心力衰竭和肾衰竭。糖尿病患者截肢主要是由长期高血糖造成的神经和血管损伤引起的，而不是由药物普遍造成的。

与该说法相关的研究

支持该说法的研究 (0)

该组中没有研究。

与该说法相矛盾或限制该说法的研究 (17)

Metformin in overweight type 2 diabetes (UKPDS 34)

UKPDS Group. Lancet 1998 · PMID 9742977

随机对照试验独立交叉核查已核查摘要★ 关键研究

Metformin reduced deaths from any cause by about a third over 10 years.

该研究是否支持这一具体说法？否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Intensive control with metformin in overweight type 2 diabetes
研究是如何开展的？
RCT within UKPDS (UKPDS 34)
研究了多少人、动物或样本？
753 (main comparison); Overweight newly diagnosed type 2 diabetes, mean age 53
实际发现了什么？
Mortality -36%.
观察到的效应有多大？
RR reduction 36% (9-55)
研究结果对日常生活意味着什么？
Metformin is protective.
该研究有哪些局限？
Small arms; Open-label; Conflicting supplementary result
它对 Elawady 的具体说法说明了什么？
Contradicts C-ODD-01, C-ODD-06; supports C-INS-11.
研究结果是否适用于德国和欧洲？
UK.
从该研究中明确不能得出什么结论？
Effects in non-overweight patients.
科学细节 →
Empagliflozin heart trial

Zinman B et al.. N Engl J Med 2015 · PMID 26378978 · DOI 10.1056/NEJMoa1504720

随机对照试验独立交叉核查已核查摘要★ 关键研究

Deaths fell from 8.3% to 5.7% over about 3 years.

该研究是否支持这一具体说法？否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
CV outcomes of empagliflozin in type 2 diabetes at high CV risk
研究是如何开展的？
Double-blind placebo-controlled RCT (EMPA-REG OUTCOME)
研究了多少人、动物或样本？
7,020; Type 2 diabetes with high CV risk
实际发现了什么？
Primary 10.
观察到的效应有多大？
HR 0.86; death -32%
研究结果对日常生活意味着什么？
This drug class protects heart and/or kidneys in the studied patients.
该研究有哪些局限？
Industry funded; Selected high-risk population
它对 Elawady 的具体说法说明了什么？
Contradicts C-ODD-06; context for C-ODD-02, C-ODD-08.
研究结果是否适用于德国和欧洲？
Multinational trial including European sites or directly applicable to EU practice.
从该研究中明确不能得出什么结论？
Benefit in low-risk people; absence of side effects.
科学细节 →
Dapagliflozin (Forxiga) in kidney disease

Heerspink HJL et al.. N Engl J Med 2020 · PMID 32970396 · DOI 10.1056/NEJMoa2024816

随机对照试验独立交叉核查全文，含结构化偏倚风险评估★ 关键研究

Forxiga reduced kidney failure and deaths; the trial was stopped early because the benefit was clear.

该研究是否支持这一具体说法？否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Dapagliflozin in CKD with/without diabetes
研究是如何开展的？
Double-blind placebo-controlled RCT (DAPA-CKD)
研究了多少人、动物或样本？
4,304; CKD (eGFR 25-75, albuminuria)
实际发现了什么？
Kidney failure, kidney decline or kidney/heart death: 9.2% with dapagliflozin vs 14.5% with placebo; deaths 4.7% vs 6.8%. Amputations 1.6% vs 1.8%; no ketoacidosis cases with dapagliflozin (2 with placebo).
观察到的效应有多大？
HR 0.61; death HR 0.69
研究结果对日常生活意味着什么？
This drug class protects heart and/or kidneys in the studied patients.
该研究有哪些局限？
Industry funded; stopped early for benefit (can overstate effect); selected high-risk CKD population; type 1 diabetes excluded; median 2.4 years follow-up.
它对 Elawady 的具体说法说明了什么？
Contradicts C-ODD-06 (Forxiga 'kills'); context for C-ODD-02.
研究结果是否适用于德国和欧洲？
Multinational trial including European sites or directly applicable to EU practice.
从该研究中明确不能得出什么结论？
Benefit in low-risk people; absence of side effects.
科学细节 →
Dapagliflozin in heart failure

McMurray JJV et al.. N Engl J Med 2019 · PMID 31535829 · DOI 10.1056/NEJMoa1911303

随机对照试验独立交叉核查已核查摘要★ 关键研究

Fewer heart failure worsenings and deaths with Forxiga.

该研究是否支持这一具体说法？否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Dapagliflozin in heart failure with reduced EF
研究是如何开展的？
Double-blind placebo-controlled RCT (DAPA-HF)
研究了多少人、动物或样本？
4,744; HFrEF NYHA II-IV, EF <=40%, with/without diabetes
实际发现了什么？
Primary 16.
观察到的效应有多大？
HR 0.74; death HR 0.83
研究结果对日常生活意味着什么？
This drug class protects heart and/or kidneys in the studied patients.
该研究有哪些局限？
Industry funded; Selected high-risk population
它对 Elawady 的具体说法说明了什么？
Contradicts C-ODD-06.
研究结果是否适用于德国和欧洲？
Multinational trial including European sites or directly applicable to EU practice.
从该研究中明确不能得出什么结论？
Benefit in low-risk people; absence of side effects.
科学细节 →
Canagliflozin in diabetic kidney disease

Perkovic V et al.. N Engl J Med 2019 · PMID 30990260 · DOI 10.1056/NEJMoa1811744

随机对照试验独立交叉核查全文，含结构化偏倚风险评估★ 关键研究

Kidney failure and heart problems fell by about a third; amputations and fractures were not increased, but rare ketoacidosis was more common (11 vs 1 cases).

该研究是否支持这一具体说法？否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Canagliflozin and renal outcomes in type 2 diabetes with nephropathy
研究是如何开展的？
Double-blind placebo-controlled RCT (CREDENCE)
研究了多少人、动物或样本？
4,401; Type 2 diabetes with albuminuric CKD
实际发现了什么？
Primary kidney/heart outcome 43.2 vs 61.2 per 1000 patient-years (30% lower); amputation 12.3 vs 11.2 per 1000 patient-years (not significant); diabetic ketoacidosis 2.2 vs 0.2 per 1000 patient-years.
观察到的效应有多大？
HR 0.70
研究结果对日常生活意味着什么？
This drug class protects heart and/or kidneys in the studied patients.
该研究有哪些局限？
Industry funded; stopped early for benefit; selected high-risk population; foot checks added during the trial may have lowered amputation risk; rare harms imprecise.
它对 Elawady 的具体说法说明了什么？
Contradicts C-ODD-06; limits amputation/fracture signals in C-ODD-05.
研究结果是否适用于德国和欧洲？
Multinational trial including European sites or directly applicable to EU practice.
从该研究中明确不能得出什么结论？
Benefit in low-risk people; absence of side effects (ketoacidosis was increased); amputation safety in routine care without foot surveillance.
科学细节 →
Liraglutide heart trial

Marso SP et al.. N Engl J Med 2016 · PMID 27295427 · DOI 10.1056/NEJMoa1603827

随机对照试验独立交叉核查全文，含结构化偏倚风险评估★ 关键研究

Fewer heart deaths and deaths overall; pancreatitis not increased, but more gallstone disease and a small, non-significant excess of pancreatic cancer.

该研究是否支持这一具体说法？否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
CV outcomes of liraglutide
研究是如何开展的？
Double-blind placebo-controlled RCT (LEADER)
研究了多少人、动物或样本？
9,340; Type 2 diabetes with high CV risk
实际发现了什么？
Heart attack, stroke or heart death 13.0% vs 14.9%; deaths 8.2% vs 9.6%; acute pancreatitis 18 vs 23 patients; pancreatic cancer 13 vs 5 (not significant); gallstone disease 3.1% vs 1.9%.
观察到的效应有多大？
HR 0.87; death HR 0.85
研究结果对日常生活意味着什么？
This drug class protects heart and/or kidneys in the studied patients.
该研究有哪些局限？
Industry funded with sponsor co-analysis; high-risk population; safety outcomes not powered and not adjusted for multiple testing; 3.5-5 years follow-up.
它对 Elawady 的具体说法说明了什么？
Contradicts C-ODD-06; limits C-ODD-04.
研究结果是否适用于德国和欧洲？
Multinational trial including European sites or directly applicable to EU practice.
从该研究中明确不能得出什么结论？
Benefit in low-risk people; that pancreatic cancer risk is absent or present (too few cases); anything about pancreatic cysts.
科学细节 →
Semaglutide heart safety trial

Marso SP et al.. N Engl J Med 2016 · PMID 27633186 · DOI 10.1056/NEJMoa1607141

随机对照试验独立交叉核查已核查摘要★ 关键研究

Fewer heart attacks/strokes, but more diabetic eye complications and stomach side effects.

该研究是否支持这一具体说法？否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
CV safety of semaglutide
研究是如何开展的？
Double-blind placebo-controlled RCT (SUSTAIN-6)
研究了多少人、动物或样本？
3,297; Type 2 diabetes, 83% with CVD/CKD
实际发现了什么？
Primary 6.
观察到的效应有多大？
HR 0.74
研究结果对日常生活意味着什么？
This drug class protects heart and/or kidneys in the studied patients.
该研究有哪些局限？
Industry funded; Selected high-risk population
它对 Elawady 的具体说法说明了什么？
Contradicts C-ODD-06; GI and retinopathy harms relevant to C-ODD-05.
研究结果是否适用于德国和欧洲？
Multinational trial including European sites or directly applicable to EU practice.
从该研究中明确不能得出什么结论？
Benefit in low-risk people; absence of side effects.
科学细节 →
How much long-term blood sugar matters (UKPDS 35)

Stratton IM et al.. BMJ 2000 · PMID 10938048 · DOI 10.1136/bmj.321.7258.405

队列研究独立交叉核查已核查摘要★ 关键研究

Each 1% lower HbA1c was linked to 21% fewer diabetes deaths and 37% fewer eye/kidney complications.

该研究是否支持这一具体说法？否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Relation of glycaemia over time to complications
研究是如何开展的？
Prospective observational analysis within UKPDS (UKPDS 35)
研究了多少人、动物或样本？
4,585 (3,642 for RR); UKPDS patients (white, Asian Indian, Afro-Caribbean)
实际发现了什么？
Graded risk with HbA1c, no threshold.
观察到的效应有多大？
-21% per 1% HbA1c
研究结果对日常生活意味着什么？
High sugar damages the body.
该研究有哪些局限？
Observational
它对 Elawady 的具体说法说明了什么？
Contradicts C-DIAB-01, C-DIAB-02, C-ODD-06 (hyperglycaemia causes complications incl. amputation).
研究结果是否适用于德国和欧洲？
UK.
从该研究中明确不能得出什么结论？
That pushing HbA1c to normal is always safe.
科学细节 →
ADA/EASD consensus 2022

Davies MJ et al.. Diabetes Care 2022 · PMID 36148880 · DOI 10.2337/dci22-0034

指南 / 立场声明独立交叉核查已核查摘要

Weight management plus heart- and kidney-protective drugs are central to type 2 diabetes care.

该研究是否支持这一具体说法？否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Management of hyperglycaemia in type 2 diabetes
研究是如何开展的？
ADA/EASD consensus report based on systematic examination of publications since 2018
研究了多少人、动物或样本？
not applicable; Adults with type 2 diabetes
实际发现了什么？
Cardiorenal protection and weight focus.
观察到的效应有多大？
not applicable
研究结果对日常生活意味着什么？
Guideline direction.
该研究有哪些局限？
Abstract only read
它对 Elawady 的具体说法说明了什么？
Contradicts C-ODD-06; supports C-INS-11.
研究结果是否适用于德国和欧洲？
EASD co-authored; directly applicable to EU.
从该研究中明确不能得出什么结论？
Not applicable.
科学细节 →
Canagliflozin heart and kidney trials (CANVAS)

Neal B et al.. N Engl J Med 2017 · PMID 28605608 · DOI 10.1056/NEJMoa1611925

随机对照试验被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究

Fewer heart attacks, strokes and heart deaths (-14%), but more toe/foot amputations.

该研究是否支持这一具体说法？部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
CV, renal and safety outcomes of canagliflozin
研究是如何开展的？
Integrated analysis of two double-blind RCTs (CANVAS Program)
研究了多少人、动物或样本？
10,142; Type 2 diabetes with high CV risk, mean age 63.3
实际发现了什么？
14% fewer heart attacks, strokes or heart deaths; about twice as many amputations (6.3 vs 3.4 per 1,000 patient-years), mostly toes; more fractures and genital infections.
观察到的效应有多大？
HR 0.86 / 1.97
研究结果对日常生活意味着什么？
Both benefits and risks; foot care matters.
该研究有哪些局限？
Funded and co-analysed by the manufacturer; two trials combined; many secondary results only exploratory.
它对 Elawady 的具体说法说明了什么？
Supports C-ODD-05 (signal); contradicts C-ODD-06 (benefit).
研究结果是否适用于德国和欧洲？
Multinational/US/UK data; transferable to EU practice.
从该研究中明确不能得出什么结论？
That SGLT2 inhibitors are net harmful.
科学细节 →
Forxiga in 17,160 people: fewer heart-failure admissions, rare ketoacidosis

Wiviott SD et al.. N Engl J Med 2019 · PMID 30415602 · DOI 10.1056/NEJMoa1812389

随机对照试验独立交叉核查已核查摘要★ 关键研究

HF hospitalisation HR 0.73; renal events HR 0.76; DKA 0.3% vs 0.1%.

Fewer HF hospitalisations and renal events; no excess death; no brain-related harm reported.

该研究是否支持这一具体说法？部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Test cardiovascular safety and benefit of dapagliflozin.
研究是如何开展的？
Blinded RCT vs placebo.
研究了多少人、动物或样本？
17,160 adults with type 2 diabetes.
实际发现了什么？
No change in heart attacks/strokes; fewer heart-failure hospitalisations and kidney events; slightly more DKA and genital infections.
观察到的效应有多大？
HHF HR 0.73 (0.61-0.88); DKA +0.2 percentage points.
研究结果对日常生活意味着什么？
The drug helps the heart and kidneys; a rare ketoacidosis risk requires precautions.
该研究有哪些局限？
Industry-funded; few DKA events.
它对 Elawady 的具体说法说明了什么？
Supports the DKA part (C-ODD-02); contradicts 'dirtiest drug' and net harm (C-ODD-06).
研究结果是否适用于德国和欧洲？
High.
从该研究中明确不能得出什么结论？
Risk during prolonged fasting.
科学细节 →
13 large trials: SGLT2 drugs protect kidneys and heart; ketoacidosis rare

Nuffield Department of Population Health Renal Studies Group; SMART-C Consortium. Lancet 2022 · PMID 36351458 · DOI 10.1016/S0140-6736(22)02074-8

Meta分析独立交叉核查已核查全文★ 关键研究

Kidney progression -37%, CV death -14%; DKA risk doubled from about 0.2 per 1,000 patient-years.

Large absolute benefits outweigh DKA and amputation.

该研究是否支持这一具体说法？部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Pool all large placebo-controlled SGLT2 inhibitor trials.
研究是如何开展的？
Collaborative meta-analysis of 13 blinded RCTs.
研究了多少人、动物或样本？
90,409 participants.
实际发现了什么？
Clear kidney and heart benefits; DKA doubled but rare; amputation signal mainly from one trial.
观察到的效应有多大？
RR 0.63 kidney; RR 0.86 CV death; DKA RR 2.12.
研究结果对日常生活意味着什么？
For 1,000 people with diabetes and kidney disease treated for a year, about 26 serious events are avoided and about 2 caused.
该研究有哪些局限？
Summary data; industry trials.
它对 Elawady 的具体说法说明了什么？
Confirms DKA risk, refutes net harm.
研究结果是否适用于德国和欧洲？
High.
从该研究中明确不能得出什么结论？
Effects in people following prolonged fasting regimens.
科学细节 →
816 trials: what each diabetes drug class does and does not do

Shi Q et al.. BMJ 2023 · PMID 37024129 · DOI 10.1136/bmj-2022-074068

Meta分析独立交叉核查已核查全文★ 关键研究

SGLT2 inhibitors and GLP-1 agonists reduce death by about 12%; each class has specific side effects.

SGLT2i and GLP-1 RA reduce all-cause death (high certainty).

该研究是否支持这一具体说法？部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Compare benefits and harms of all diabetes drug classes.
研究是如何开展的？
Network meta-analysis of 816 RCTs with GRADE.
研究了多少人、动物或样本？
471,038 patients.
实际发现了什么？
Mortality benefit for SGLT2i and GLP-1 RA; class-specific harms such as DKA and genital infections (SGLT2i), hypoglycaemia (sulfonylureas, insulin), heart failure (TZDs).
观察到的效应有多大？
Death OR 0.88; DKA OR 2.07; amputation OR 1.27.
研究结果对日常生活意味着什么？
No drug is free of side effects; for several classes the benefits clearly outweigh them in people at risk.
该研究有哪些局限？
Low certainty for older drugs.
它对 Elawady 的具体说法说明了什么？
Supports 'every class has harms'; refutes 'net harmful'.
研究结果是否适用于德国和欧洲？
High.
从该研究中明确不能得出什么结论？
Individual treatment choice.
科学细节 →
No sign in trials that SGLT2 drugs damage the brain

Seminer A et al.. JAMA Neurol 2025 · PMID 40193122 · DOI 10.1001/jamaneurol.2025.0360

Meta分析独立交叉核查已核查摘要

Dementia OR 1.20 (0.67-2.17) for SGLT2i, not significant; GLP-1 RA OR 0.55.

No randomised signal of brain harm with SGLT2i (OR 1.20, 0.67-2.17), imprecise.

该研究是否支持这一具体说法？否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Assess dementia risk with cardioprotective diabetes drugs in RCTs.
研究是如何开展的？
Meta-analysis of 26 RCTs.
研究了多少人、动物或样本？
164,531 participants.
实际发现了什么？
No effect overall; benefit with GLP-1 RAs; SGLT2i neutral but imprecise.
观察到的效应有多大？
SGLT2i OR 1.20 (0.67-2.17).
研究结果对日常生活意味着什么？
Trials do not show brain damage from Forxiga-type drugs.
该研究有哪些局限？
Dementia rarely measured systematically.
它对 Elawady 的具体说法说明了什么？
Does not support 'kills the brain'.
研究结果是否适用于德国和欧洲？
High.
从该研究中明确不能得出什么结论？
A small effect in either direction.
科学细节 →
Most leg amputations in a Swedish region were in people without diabetes

Johannesson A et al.. Diabetes Care 2009 · PMID 19001192 · DOI 10.2337/dc08-1639

队列研究独立交叉核查已核查摘要

157 of 290 amputees had no diabetes; risk 8 times higher with diabetes.

157 of 290 amputees had no diabetes.

该研究是否支持这一具体说法？否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Compare amputation rates with and without diabetes.
研究是如何开展的？
10-year regional registry.
研究了多少人、动物或样本？
290 amputees.
实际发现了什么？
Amputations occur in people without diabetes too; diabetes raises the rate eightfold.
观察到的效应有多大？
About 195 vs 23 per 100,000 person-years.
研究结果对日常生活意味着什么？
Amputations are caused by blood-vessel disease and diabetes, not only by medicines.
该研究有哪些局限？
Drug use not studied.
它对 Elawady 的具体说法说明了什么？
Refutes 'only'.
研究结果是否适用于德国和欧洲？
High.
从该研究中明确不能得出什么结论？
Effects of individual drugs.
科学细节 →
GLP-1 injections in 60,080 people: fewer deaths, no more pancreas problems

Sattar N et al.. Lancet Diabetes Endocrinol 2021 · PMID 34425083 · DOI 10.1016/S2213-8587(21)00203-5

Meta分析独立交叉核查已核查摘要★ 关键研究

Death HR 0.88; MACE HR 0.86; no increase in pancreatic adverse effects.

All-cause death HR 0.88.

该研究是否支持这一具体说法？否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Pool GLP-1 RA outcome trials.
研究是如何开展的？
Meta-analysis of 8 RCTs.
研究了多少人、动物或样本？
60,080 patients.
实际发现了什么？
Benefits on heart, kidney and survival; no pancreatic safety signal.
观察到的效应有多大？
MACE -14%, death -12%.
研究结果对日常生活意味着什么？
In large trials these drugs prolonged life and did not cause more pancreatitis.
该研究有哪些局限？
Exact pancreatitis numbers not in abstract.
它对 Elawady 的具体说法说明了什么？
Contradicts a clear pancreatitis risk and net harm.
研究结果是否适用于德国和欧洲？
High.
从该研究中明确不能得出什么结论？
Very rare effects.
科学细节 →
NICE 2026: offer metformin plus an SGLT-2 inhibitor to most adults with type 2 diabetes

National Institute for Health and Care Excellence (NICE). NICE guideline 2026

指南 / 立场声明独立交叉核查已核查摘要★ 关键研究

Fewer heart events and heart-failure admissions; DKA and Fournier gangrene 1 per 1,000 or fewer.

Metformin plus SGLT-2 inhibitor recommended first-line; benefits outweigh risks.

该研究是否支持这一具体说法？否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Recommend first-line diabetes medicines.
研究是如何开展的？
Guideline based on meta-analyses.
研究了多少人、动物或样本？
Not applicable.
实际发现了什么？
Benefits outweigh risks for most people.
观察到的效应有多大？
HF hospitalisation 54 vs 26-40 per 1,000 over 3 years.
研究结果对日常生活意味着什么？
These medicines are recommended because they prevent heart problems.
该研究有哪些局限？
UK context.
它对 Elawady 的具体说法说明了什么？
Contradicts net harm.
研究结果是否适用于德国和欧洲？
High.
从该研究中明确不能得出什么结论？
Individual choices.
科学细节 →

结果不一或不明确的研究 (1)

Very aggressive blood sugar lowering in high-risk type 2 diabetes

Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743

随机对照试验被 Tayebat 档案网站引用已核查全文★ 关键研究

Pushing HbA1c below 6% increased deaths by about one-fifth and did not reduce heart attacks or strokes significantly.

该研究是否支持这一具体说法？部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

原始文献 · 科学细节

研究通俗解读
研究人员想了解什么？
Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?
研究是如何开展的？
Multicentre randomised controlled trial (open-label treatment strategies), mean 3.5 years of intensive therapy
研究了多少人、动物或样本？
10,251; Type 2 diabetes, mean age 62.2, median HbA1c 8.1%, established CVD or additional risk factors
实际发现了什么？
More deaths (HR 1.22) and more severe hypoglycaemia with intensive therapy; primary CV outcome not significantly reduced.
观察到的效应有多大？
HR 1.22 (1.01-1.46) all-cause death; HR 0.90 (0.78-1.04) primary outcome
研究结果对日常生活意味着什么？
Very strict sugar targets are not good for everyone, especially older people with heart disease.
该研究有哪些局限？
Strategy trial: cannot attribute harm to a specific drug; Intensive arm stopped early; High-risk population; not generalisable to early diabetes
它对 Elawady 的具体说法说明了什么？
Core evidence that near-normal HbA1c targets can harm high-risk type 2 patients (C-INS-04).
研究结果是否适用于德国和欧洲？
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
从该研究中明确不能得出什么结论？
That insulin specifically caused the deaths, or that lowering high glucose to moderate targets is harmful.
科学细节 →

地区背景

德国 / 欧盟

埃及

在我的国家适用什么？

一般科学评估

错误错误：在大型试验中，达格列净和其他几种糖尿病药物能减少死亡、心力衰竭和肾衰竭；没有证据表明达格列净会损害大脑，而从未服用过糖尿病药物的人也会发生截肢。

该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。

参考文献

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742977
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.. Zinman B et al.. N Engl J Med 2015 · PMID 26378978 · DOI 10.1056/NEJMoa1504720
Dapagliflozin in Patients with Chronic Kidney Disease.. Heerspink HJL et al.. N Engl J Med 2020 · PMID 32970396 · DOI 10.1056/NEJMoa2024816
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.. McMurray JJV et al.. N Engl J Med 2019 · PMID 31535829 · DOI 10.1056/NEJMoa1911303
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.. Perkovic V et al.. N Engl J Med 2019 · PMID 30990260 · DOI 10.1056/NEJMoa1811744
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.. Marso SP et al.. N Engl J Med 2016 · PMID 27295427 · DOI 10.1056/NEJMoa1603827
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.. Marso SP et al.. N Engl J Med 2016 · PMID 27633186 · DOI 10.1056/NEJMoa1607141
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.. Stratton IM et al.. BMJ 2000 · PMID 10938048 · DOI 10.1136/bmj.321.7258.405
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).. Davies MJ et al.. Diabetes Care 2022 · PMID 36148880 · DOI 10.2337/dci22-0034
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.. Neal B et al.. N Engl J Med 2017 · PMID 28605608 · DOI 10.1056/NEJMoa1611925
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.. Wiviott SD et al.. N Engl J Med 2019 · PMID 30415602 · DOI 10.1056/NEJMoa1812389
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.. Nuffield Department of Population Health Renal Studies Group; SMART-C Consortium. Lancet 2022 · PMID 36351458 · DOI 10.1016/S0140-6736(22)02074-8
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.. Shi Q et al.. BMJ 2023 · PMID 37024129 · DOI 10.1136/bmj-2022-074068
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis.. Seminer A et al.. JAMA Neurol 2025 · PMID 40193122 · DOI 10.1001/jamaneurol.2025.0360
Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations.. Johannesson A et al.. Diabetes Care 2009 · PMID 19001192 · DOI 10.2337/dc08-1639
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.. Sattar N et al.. Lancet Diabetes Endocrinol 2021 · PMID 34425083 · DOI 10.1016/S2213-8587(21)00203-5
Type 2 diabetes in adults: management (NICE guideline NG28), published 2 December 2015, last updated 18 February 2026. National Institute for Health and Care Excellence (NICE). NICE guideline 2026
Effects of intensive glucose lowering in type 2 diabetes.. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743

← 返回概览

降糖药总体有害，应归入“禁止”之列；达格列净（Forxiga）是“最脏”的药物之一，会杀死大脑；只有服用糖尿病药物和胰岛素的人才会截肢。

原始表述

译文

出处

来源版本存在差异

科学评估

1. 说法是什么？

2. 哪些内容可证实是正确的？

3. 哪些内容是错误或夸大的？

4. 哪些内容仍不明确？

5. 哪些研究支持该说法？

6. 哪些研究与该说法相矛盾？

7. 对德国和欧洲而言情况如何？

8. 关于埃及的已知情况是什么？

9. 合理的实际结论是什么？

评估详情

科学证据详解

哪些证据支持该说法？

Canagliflozin heart and kidney trials (CANVAS)

Very aggressive blood sugar lowering in high-risk type 2 diabetes

哪些证据不支持该说法？

816 trials: what each diabetes drug class does and does not do

13 large trials: SGLT2 drugs protect kidneys and heart; ketoacidosis rare

Dapagliflozin in heart failure

总体证据说明了什么？

哪种观点有更好的证据支持？

为什么有些研究权重更大

仍存在的不确定性

合理的结论

待解决的问题

核查深度如何？

通俗解释

与该说法相关的研究

支持该说法的研究 (0)

与该说法相矛盾或限制该说法的研究 (17)

Metformin in overweight type 2 diabetes (UKPDS 34)

Empagliflozin heart trial

Dapagliflozin (Forxiga) in kidney disease

Dapagliflozin in heart failure

Canagliflozin in diabetic kidney disease

Liraglutide heart trial

Semaglutide heart safety trial

How much long-term blood sugar matters (UKPDS 35)

ADA/EASD consensus 2022

Canagliflozin heart and kidney trials (CANVAS)

Forxiga in 17,160 people: fewer heart-failure admissions, rare ketoacidosis

13 large trials: SGLT2 drugs protect kidneys and heart; ketoacidosis rare

816 trials: what each diabetes drug class does and does not do

No sign in trials that SGLT2 drugs damage the brain

Most leg amputations in a Swedish region were in people without diabetes

GLP-1 injections in 60,080 people: fewer deaths, no more pancreas problems

NICE 2026: offer metformin plus an SGLT-2 inhibitor to most adults with type 2 diabetes

结果不一或不明确的研究 (1)

Very aggressive blood sugar lowering in high-risk type 2 diabetes

地区背景

德国 / 欧盟

埃及

在我的国家适用什么？

一般科学评估

参考文献